RALU Study: Sequential use of radium-223 and lutetium-177 in mCRPC treatment

RALU Study Sequential use of radium-223 and lutetium-177 in mCRPC treatment

Are you looking for a clear, visual guide to optimize treatment for men with metastatic castration-resistant prostate cancer (mCRPC)?

This severe form of prostate cancer, which largely affects the bone, requires precise and strategic treatment planning.

Download our free, comprehensive infographic today to gain a clearer understanding of the therapeutic sequencing of radioligand therapies (RLTs). 

Download the infographic to transform your clinical decision-making and enhance patient care strategies.

Supported by unrestricted educational funding from Bayer.